Cidara Therapeutics, Inc.
CDTX
株式のランク
#3181
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
株価
$221.38
最終同期: 2026-01-08
時価総額
$5.61B
変化（1日）
0.00%
変化（1年）
120.15%
国
US
取引 Cidara Therapeutics, Inc. (CDTX)
カテゴリー
Healthcare
Cidara Therapeutics, Inc.（CDTX）の収益
Sep 2025 時点の収益 TTM: 0.00
Cidara Therapeutics, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0.00 です。2023 年には $23.28M の収益があり、これは 2022 年の $64.45M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Cidara Therapeutics, Inc. の収益履歴（2012 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | $1.28M | -94.52% |
| 2023 | $23.28M | -63.87% |
| 2022 | $64.45M | 30.01% |
| 2021 | $49.57M | 310.81% |
| 2020 | $12.07M | -42.30% |
| 2019 | $20.92M | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| - | - |
CH
|
|
| $6.02B | - |
NL
|
